Literature DB >> 22286691

μMLC-LINAC radiosurgery for intracranial meningiomas of complex shape.

Faycal El Majdoub1, Moataz Elawady, Christian Bührle, Mustapha El-Khatib, Mauritius Hoevels, Harald Treuer, Rolf-Peter Müller, Volker Sturm, Mohammad Maarouf.   

Abstract

BACKGROUND: We present the long-term results of a consecutive series of patients with meningiomas treated by LINAC-radiosurgery using the micro-multi-leaf collimator technique (μMLC).
METHODS: Between May 2001 and July 2009, 78 patients (m: f = 024:54; median age, 56.8 years; range, 20.1-81 years) with 87 intracranial meningiomas (78 WHO I, seven WHO II, two WHO III) were treated with μMLC-LINAC radiosurgery at our institution, either as a primary or salvage treatment following one or more microsurgical procedures. Fifty-eight of 87 tumors (66.7%) were located in the skull base. The remaining 29 meningiomas (33.3%) were located in the convexity of the brain. The median tumor volume was 4.8 ml (range, 0.2-18.3 ml). The median tumor surface dose, maximal dose, and therapeutic isodose were 12 Gy, 16 Gy, and 75%, respectively.
RESULTS: For retrospective evaluation, we included 70 patients (78 tumors) with a minimum radiological follow-up of 24 months. After a median follow-up of 79.7 months (range, 24.2-109.1 months), 24 patients (34.3%) improved in their clinical status (paresis of N. abducens 18/48, facial paresis 4/8, and hemiparesis 2/9), 41 patients remained stable (58.6%), three patients had treatment-related temporary complaints (4.3%); two patients developed vertigo, and one had a left-sided hemihypesthesia. All complaints recovered completely after steroid medication within 2 weeks. Two patients (2.8%) developed permanent trigeminal neuralgia. Follow-up MR images showed a partial remission in 21 tumors (26.9%) and a stable tumor size in 55 cases (70.5%). Two patients with high-grade meningiomas showed a tumor progression (one WHO II and one WHO III meningioma). At the end of follow-up (July 2010), the actuarial 5- and 9-year progression-free survival after radiosurgery were 98 and 96%, respectively. There was no treatment-related mortality.
CONCLUSIONS: LINAC radiosurgery using a micro multi-leaf collimator for complex shaped intracranial meningiomas is effective yielding a high local tumor control, whereas the treatment-related morbidity remains low.

Entities:  

Mesh:

Year:  2012        PMID: 22286691     DOI: 10.1007/s00701-012-1278-4

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  5 in total

1.  Partial skull base tumour resection in combination with radiosurgery: an escape procedure or a reasonable solution of treatment?

Authors:  Gorazd Bunc; Janez Ravnik; Maja Ravnik; Tomaz Velnar
Journal:  Wien Klin Wochenschr       Date:  2015-04-30       Impact factor: 1.704

2.  Intracranial stereotactic radiosurgery with an adapted linear accelerator vs. robotic radiosurgery: Comparison of dosimetric treatment plan quality.

Authors:  Harald Treuer; Moritz Hoevels; Klaus Luyken; Veerle Visser-Vandewalle; Jochen Wirths; Martin Kocher; Maximilian Ruge
Journal:  Strahlenther Onkol       Date:  2014-11-22       Impact factor: 3.621

3.  Stereotactic LINAC radiosurgery for the treatment of typical intracranial meningiomas. Efficacy and safety after a follow-up of over 12 years.

Authors:  Mustafa El-Khatib; Faycal El Majdoub; Stefan Hunsche; Mauritius Hoevels; Martin Kocher; Volker Sturm; Mohammad Maarouf
Journal:  Strahlenther Onkol       Date:  2015-08-08       Impact factor: 3.621

4.  Survival of Patients with Primary Brain Tumors: Comparison of Two Statistical Approaches.

Authors:  Iveta Selingerová; Hana Doleželová; Ivanka Horová; Stanislav Katina; Jiří Zelinka
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

5.  Linear Accelerator-Based Radiosurgery of Grade I Intracranial Meningiomas.

Authors:  Sara Alatriste-Martínez; Sergio Moreno-Jiménez; Guillermo A Gutiérrez-Aceves; José de Jesús Suárez-Campos; Olivia Amanda García-Garduño; Alejandro Rosas-Cabral; Miguel Ángel Celis-López
Journal:  World Neurosurg X       Date:  2019-03-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.